SUMMARY HIV-1 DNA persists in infected cells despite combined antiretroviral therapy
(cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs …

Although antiretroviral therapy (ART) can reduce viremia to below the limit of detection and
allow persons living with HIV-1 (PLWH) to lead relatively normal lives, viremia rebounds …

The development of persistent cellular reservoirs of latent human immunodeficiency virus
(HIV) is a critical obstacle to viral eradication since viral rebound takes place once anti …

Importance New data and therapeutic options warrant updated recommendations for the use
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …

Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from
infected cells and tissues. Here, sequential long-acting slow-effective release antiviral …

Despite years of plasma HIV-RNA levels< 40 copies per milliliter during combination
antiretroviral therapy (cART), the majority of HIV-infected patients exhibit persistent …

Highly potent and broadly neutralizing anti-HIV-1 antibodies (bNAbs) have been used to
prevent and treat lentivirus infections in humanized mice, macaques, and humans,,,,,,,,,,,. In …

HIV-1 proviruses persist in the CD4+ T cells of HIV-infected individuals despite years of
combination antiretroviral therapy (cART) with suppression of HIV-1 RNA levels< 40 …

Objectives: Therapies to achieve sustained antiretroviral therapy-free HIV remission will
require validation in analytic treatment interruption (ATI) trials. Identifying biomarkers that …

Although antiretroviral therapy (ART) is highly effective at suppressing HIV-1 replication, the
virus persists as a latent reservoir in resting CD4+ T cells during therapy. This reservoir …